Business
Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product
NEWPORT BEACH, Calif., August 20, 2025--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.
About this update from Evolus, Inc. Common Stock
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1024,"height":512,"url":"https://media.zenfs.com/en/business-wire.com/d2402d7f96e7fa665623ffe69b1d7fa0"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xSLSEMgn_Xo0c6U4crabOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/d2402d7f96e7fa665623ffe69b1d7fa0","width":960,"height":480},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/vwB40NHtnQTlH0eOSN9BaA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwNDg7aD0xMDI0O2NmPXdlYnA-/https://media.zenfs.com/en/business-wire.com/d2402d7f96e7fa665623ffe69b1d7fa0","width":1024,"height":512}},"lazy":false},{"type":"text","content":"NEWPORT BEACH, Calif., August 20, 2025--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it has submitted the final module of its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.","length":434,"tagName":"p"},{"type":"text","content":""This submission represents an important milestone in expanding our Evolysse™ collection of injectable HA gels," said Dr. Rui Avelar, MD, Chief Medical Officer and Head of R&D. "Sculpt is our most structured product, manufactured using a novel technology and designed to address mid-face volume loss, a high-value segment in facial aesthetics."","length":368,"tagName":"p"},{"type":"text","content":"Evolus anticipates that the FDA’s review will follow the standard PMA process, with approval expected in the second half of 2026. The submission underscores Evolus’ commitment to bringing its collection of injectable hyaluronic acid gel products to market and its readiness to meet rigorous regulatory requirements.","length":315,"tagName":"p"},{"type":"text","content":"In support of the PMA application, a U.S. pivotal study which evaluated the safety and effectiveness of the product in a multicenter, double-blinded, controlled, non-inferiority designed trial was conducted. Patients were followed for 24 months from initial treatment. A total of 304 patients were enrolled and randomized to receive Evolysse...